FDA Enforcement Now Includes Med Spas

What changed: The Drug Supply Chain Security Act (DSCSA) is now being enforced at the medical practice level. Any practice that purchases, stores, or administers drug products in-office is now subject to FDA supply chain compliance inspections not just manufacturers, wholesale distributors, and pharmacies.

The Drug Products at Issue in Med Spa & Aesthetics Practices

If your practice purchases and administers any of the following, federal drug supply chain requirements apply to you regardless of whether you operate a pharmacy:

Injectable & Aesthetic Treatments

• Neurotoxins (Botox, Dysport, Xeomin, Daxxify)

• Dermal fillers (Juvéderm, Restylane, Sculptra)

• Kybella (deoxycholic acid)

• Platelet-rich plasma (PRP) therapies

Specialty & Emerging Products

• Weight loss medications (GLP-1s: semaglutide, tirzepatide)

• Prescription-strength retinoids

• Prescription-strength hydroquinone

• Eyelash enhancers (Latisse / bimatoprost)

• Peptide therapies (Ipamorelin, BPC-157, Sermorelin)

Medical spas are among the highest-risk practice types for DSCSA enforcement.

Med spas were among the first targets of expanded enforcement. The use of neurotoxins, fillers, and biologic agents often sourced through a mix of authorized and gray-market channels creates significant traceability exposure. If an inspector walks in today, can you show a clean chain of custody for every vial of Botox?

High reliance on neurotoxins and biologics subject to strict serialization requirements
Frequent gray-market sourcing creates authorized trading partner gaps
Purchase-to-administration reconciliation rarely maintained at the unit level
FDA's first physician-practice 483 was issued to an aesthetics operation

FDA Enforcement Now Includes Med Spas

Medical spas are among the highest-risk practice types for DSCSA enforcement.

This website uses cookies.